RESUMEN
With a poor prognosis, glioblastoma multiforme is the most aggressive tumor of the central nervous system in humans. The aim of this study was to develop novel tracers for the tumor targeting and imaging of overexpressed serotonin-7 receptors (5-HT7Rs) in U-87 MG glioma xenografted nude mice. Two phenylpiperazine derivatives named as PHH and MPHH were designed, and the corresponding radiotracers 99mTc-PHH and 99mTc-MPHH were synthesized in high radiochemical purity (>95%). 99mTc-MPHH showed a higher affinity to 5-HT7Rs on U-87 MG cells compared to 99mTc-PHH. In biodistribution studies, the radiocomplexes showed good brain uptake at 15 min combined with good radioactivity retention in the brain for 240 min. Regional rabbit brain studies indicated a higher radioactivity concentration in the hippocampus and diencephalon than in the cerebellum. Compared to 99mTc-MPHH, the 99mTc-PHH exhibited a significantly increased tumor uptake at 15 and 60 min, but the rapid blood clearance of 99mTc-MPHH led to enhanced tumor-to-muscle ratios at 240 min. A significant reduction in tumor uptake 60 min after an injection of pimozide (5-HT7 receptor antagonist) confirms the tumor uptake was receptor-mediated specifically. The tumor-to-contralateral muscle tissue ratio of 99mTc-PHH and 99mTc-MPHH in nude mice with U-87 MG xenograft was measured (5.25 and 4.65) at 60 min as well as (6.25 and 6.76) at 240 min, respectively.
Asunto(s)
Neoplasias Encefálicas/diagnóstico por imagen , Glioblastoma/diagnóstico por imagen , Piperazinas/administración & dosificación , Radiofármacos/administración & dosificación , Receptores de Serotonina/metabolismo , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Encéfalo/patología , Neoplasias Encefálicas/patología , Línea Celular Tumoral , Glioblastoma/patología , Humanos , Ligandos , Masculino , Ratones , Pimozida/administración & dosificación , Piperazinas/síntesis química , Piperazinas/farmacocinética , Tomografía de Emisión de Positrones/métodos , Conejos , Radiofármacos/síntesis química , Radiofármacos/farmacocinética , Antagonistas de la Serotonina/administración & dosificación , Tecnecio , Distribución Tisular/efectos de los fármacos , Tomografía Computarizada de Emisión de Fotón Único/métodos , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Glioblastoma is the most common primary brain tumor in adults. While the introduction of temozolomide chemotherapy has increased long-term survivorship, treatment failure and rapid tumor recurrence remains universal. The transcriptional regulatory protein, inhibitor of DNA-binding-1 (ID1), is a key regulator of cell phenotype in cancer. We show that CRISPR-mediated knockout of ID1 in glioblastoma cells, breast adenocarcinoma cells, and melanoma cells dramatically reduced tumor progression in all three cancer systems through transcriptional downregulation of EGF, which resulted in decreased EGFR phosphorylation. Moreover, ID1-positive cells were enriched by chemotherapy and drove tumor recurrence in glioblastoma. Addition of the neuroleptic drug pimozide to inhibit ID1 expression enhanced the cytotoxic effects of temozolomide therapy on glioma cells and significantly prolonged time to tumor recurrence. Conclusively, these data suggest ID1 could be a promising therapeutic target in patients with glioblastoma. SIGNIFICANCE: These findings show that the transcriptional regulator ID1 is critical for glioblastoma initiation and chemoresistance and that inhibition of ID1 enhances the effect of temozolomide, delays tumor recurrence, and prolongs survival.
Asunto(s)
Neoplasias Encefálicas/tratamiento farmacológico , Resistencia a Antineoplásicos/fisiología , Glioblastoma/tratamiento farmacológico , Proteína 1 Inhibidora de la Diferenciación/metabolismo , Animales , Antineoplásicos Alquilantes/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Neoplasias Encefálicas/mortalidad , Neoplasias Encefálicas/patología , Neoplasias de la Mama/patología , Resistencia a Antineoplásicos/efectos de los fármacos , Receptores ErbB/metabolismo , Femenino , Regulación Neoplásica de la Expresión Génica , Glioblastoma/mortalidad , Glioblastoma/patología , Humanos , Proteína 1 Inhibidora de la Diferenciación/antagonistas & inhibidores , Proteína 1 Inhibidora de la Diferenciación/genética , Melanoma/patología , Ratones Endogámicos NOD , Fosforilación , Pimozida/administración & dosificación , Pimozida/farmacología , Temozolomida/administración & dosificación , Temozolomida/farmacología , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disorder in which the neuromuscular junction progressively degenerates, leading to movement difficulties, paralysis, and eventually death. ALS is currently being treated by only two FDA-approved drugs with modest efficacy in slowing disease progression. Often, the translation of preclinical findings to bedside terminates prematurely as the evaluation of potential therapeutic compounds focuses on a single study or a single animal model. To circumscribe these issues, we screened 3,765 novel small molecule derivatives of pimozide, a recently identified repurposed neuroleptic for ALS, in Caenorhabditis elegans, confirmed the hits in zebrafish and validated the most active compounds in mouse genetic models. Out of the 27 small molecules identified from the high-throughput screen in worms, 4 were found to recover locomotor defects in C. elegans and genetic zebrafish models of ALS. TRVA242 was identified as the most potent compound as it significantly improved efficiency in rescuing locomotor, motorneuron, and neuromuscular junction synaptic deficits in a C. elegans TDP-43 model and in multiple zebrafish genetic (TDP-43, SOD1, and C9ORF72) models of ALS. The actions of TRVA242 were also conserved in a mammalian model as it also stabilized neuromuscular junction deficits in a mouse SOD1 model of ALS. Compounds such as TRVA242 therefore represent new potential therapeutics for the treatment of ALS.
Asunto(s)
Esclerosis Amiotrófica Lateral/tratamiento farmacológico , Esclerosis Amiotrófica Lateral/genética , Proteína C9orf72/genética , Modelos Animales de Enfermedad , Unión Neuromuscular/genética , Superóxido Dismutasa-1/genética , Esclerosis Amiotrófica Lateral/metabolismo , Animales , Animales Modificados Genéticamente , Caenorhabditis elegans , Proteínas de Unión al ADN/administración & dosificación , Proteínas de Unión al ADN/metabolismo , Humanos , Locomoción/efectos de los fármacos , Locomoción/fisiología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Unión Neuromuscular/efectos de los fármacos , Unión Neuromuscular/metabolismo , Técnicas de Cultivo de Órganos , Pimozida/administración & dosificación , Pimozida/metabolismo , Pez CebraRESUMEN
Wild carp (Cyprinus carpio carpio) forms the basis of an important fishery in the Southern Caspian Sea Basin which is increasingly underpinned by the release of cultured juveniles. A significant bottleneck to hatchery-rearing of juveniles is the spermiation of male broodstock. Therefore, four approaches to improving spermiation were investigated. The effectiveness of two delivery methods for the sustained release of salmon gonadotropin releasing hormone analogue (sGnRHa; i.e., via intramuscular cholesterol pellet vs emulsion injection) on the spermiation success and duration, sperm quality and quantity over 14days in wild-caught carp were compared to single injection of sGnRHa with Pimozide(®) (Linpe method) or carp pituitary extract (CPE). The consequence of the spermiation treatments on resulting embryonic quality was evaluated for subsequent fertilization and hatching success from wild male carp (mean weight±S.D. 1021±112g). All hormonal treatments, except for Linpe method, led to 100% spermiation of treated fish compared to only 25% in the control with no hormone intervention. The duration of spermiation, as well as the various quantitative variables of the sperm and the mean total sperm production were all generally improved with the sustained hormone delivery compared with the acute treatments. The GnRHa-FIA was the most effective method for improving spermiation.
Asunto(s)
Carpas/fisiología , Especies en Peligro de Extinción , Hormona Liberadora de Gonadotropina/análogos & derivados , Pimozida/farmacología , Espermatogénesis/efectos de los fármacos , Animales , Implantes de Medicamentos , Hormona Liberadora de Gonadotropina/administración & dosificación , Hormona Liberadora de Gonadotropina/farmacología , Masculino , Océanos y Mares , Pimozida/administración & dosificación , Hipófisis , Especificidad de la Especie , Extractos de Tejidos/administración & dosificación , Extractos de Tejidos/farmacologíaRESUMEN
Currently, drug discovery and development for clinical treatment of prostate cancer has received increased attention, specifically the STAT3 inhibitor. Our previous study reported that the neuroleptic drug pimozide had antitumor activity against hepatocellular carcinoma cells or stem-like cells through suppressing the STAT3 activity. In the present study we demonstrate that pimozide inhibits cell growth and cellular STAT3 activation in prostate cancer cells. Our results showed that pimozide inhibited prostate cancer cell proliferation in a dose- and time-dependent manner by inducing G1 phase cell cycle arrest, downregulated the ability of colony formation and sphere forming, as well as suppressed cells migration in both DU145 and LNCaP cells. Surprisingly, pimozide reduced the basal expression of phosphorylation STAT3 at tyrosine 705 and reversed the expression of phosphorylation of STAT3 induced by IL-6 addition, suggesting that pimozide can suppress cellular STAT3 activation. Thus, the antipsychotic agent pimozide may be a potential and novel therapeutic for patients with advanced prostate cancer.
Asunto(s)
Interleucina-6/metabolismo , Neoplasias de la Próstata/tratamiento farmacológico , Factor de Transcripción STAT3/biosíntesis , Animales , Antipsicóticos/administración & dosificación , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Interleucina-6/genética , Masculino , Ratones , Fosforilación , Pimozida/administración & dosificación , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Factor de Transcripción STAT3/genética , Ensayos Antitumor por Modelo de XenoinjertoAsunto(s)
Antipsicóticos/efectos adversos , Aripiprazol/efectos adversos , Pimozida/efectos adversos , Tics/inducido químicamente , Síndrome de Tourette/inducido químicamente , Adolescente , Antipsicóticos/administración & dosificación , Antipsicóticos/uso terapéutico , Aripiprazol/administración & dosificación , Humanos , Masculino , Pimozida/administración & dosificación , Síndrome de Tourette/tratamiento farmacológicoRESUMEN
Clinical pharmacology as an interdisciplinary science is unique in its capacity and the diversity of the methods and approaches it can provide to derive dosing recommendations in various subpopulations. This article illustrates cases where an integrated clinical pharmacology approach was used to derive dosing recommendations for psychiatry drugs within regulatory settings. The integrated approach is based on the view that once a drug is shown to be effective in the general population, it is reasonable to take into consideration other relevant findings and the use of alternative scientific tools and analysis to derive dosing recommendations in specific populations. The method provides useful means to solve the challenges of the paucity of available data and lead to clear dosing instructions. This in turn expands the benefits of any given drug to all individuals in which the drug is likely to be effective.
Asunto(s)
Antipsicóticos/administración & dosificación , Farmacología Clínica/métodos , Estimulantes del Sistema Nervioso Central/administración & dosificación , Aprobación de Drogas , Humanos , Isoindoles/administración & dosificación , Isoxazoles/administración & dosificación , Clorhidrato de Lurasidona , Metilfenidato/administración & dosificación , Palmitato de Paliperidona , Pimozida/administración & dosificación , Pirimidinas/administración & dosificación , Tiazoles/administración & dosificaciónRESUMEN
INTRODUCTION: A substantial number of patients with treatment-resistant schizophrenia respond only partially to clozapine. Therefore, it has been common practice to use augmentation strategies to maximize clozapine's effect. But the efficacy of this strategy remains poorly established. We have conducted a randomized double-blind placebo controlled clinical trial in patients with schizophrenia currently receiving clozapine with partial response, and tested the efficacy of pimozide augmentation on positive and negative symptoms and also on neurocognitive measures. METHODS: Thirty-two outpatients enrolled in the clinical trial and 28 completed. Patients with adequate blood levels of clozapine were randomized to pimozide vs placebo and participated in the trial for 12 weeks receiving monthly assessments for Brief Psychiatric Rating Scale (BPRS) and Schedule for Assessment of Negative Symptoms (SANS), and weekly assessments for electrocardiogram (EKG), and side effects. Neurocognitive tests measuring verbal fluency, working memory, motor and attention/executive function were obtained at study entry and end of the trial. RESULTS: We found no significant effect of pimozide on BPRS total, psychosis and depression subscale items, SANS scores or QTc interval. Neurocognitive measures did not show significant improvement either. DISCUSSION: In this well controlled clinical trial of patients with treatment-resistant schizophrenia currently receiving clozapine, pimozide augmentation was not an effective strategy to maximize the benefit for better control of positive and negative symptoms or improving neurocognitive function.
Asunto(s)
Antipsicóticos/administración & dosificación , Clozapina/administración & dosificación , Pimozida/administración & dosificación , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/efectos adversos , Escalas de Valoración Psiquiátrica Breve , Clozapina/efectos adversos , Método Doble Ciego , Sinergismo Farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Pruebas Neuropsicológicas , Pimozida/efectos adversos , Resultado del TratamientoRESUMEN
OBJECTIVE: The occurrence of pimozide-induced arrhythmias is concentration dependent. Hence, it is important for prescribers to consider causes of increased pimozide exposure. This article summarizes the U.S. Food and Drug Administration's (FDA's) review of drug interaction and pharmacogenomic studies and discusses pharmacokinetic simulations we performed to develop new cytochrome P450 2D6 (CYP2D6) genotype-guided dosing recommendations for pimozide. METHOD: Pharmacokinetic parameters by CYP2D6 genotype were derived from a published single-dose pharmacogenomic study of pimozide. We simulated what pimozide exposures would result from a multiple-dose scenario in different CYP2D6 genotype groups: extensive, intermediate, and poor metabolizers. The maximum dose for poor metabolizers was defined as the dose that would not exceed pimozide concentrations following 10 mg daily in extensive metabolizers and intermediate metabolizers (the current maximum dose in an unselected population). RESULTS: Dose-ranging analyses revealed that 4 mg daily in CYP2D6 poor metabolizers was the maximum dose that would not result in plasma concentrations in excess of those observed in extensive metabolizer and intermediate metabolizer patients receiving 10 mg daily. CYP2D6 genotyping is now consequently recommended in the pimozide product label before exceeding 4 mg of pimozide daily in adults or 0.05 mg/kg/d in children. Previously, dose adjustment was recommended every 3 days to achieve the desired clinical response for all patients. The label was modified to subsequently reflect that pimozide doses should not be increased earlier than 14 days in patients who are known CYP2D6 poor metabolizers. CONCLUSIONS: Given the risk of increased pimozide concentrations and longer time to steady state in CYP2D6 poor metabolizers, the FDA has revised the pimozide label to provide clinicians with clearer dosing, titration, and genotype testing recommendations. The new information is intended to enhance therapeutic individualization of pimozide in pediatric and adult patients.
Asunto(s)
Citocromo P-450 CYP2D6/genética , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/farmacocinética , Síndrome de QT Prolongado/prevención & control , Pimozida/administración & dosificación , Pimozida/farmacocinética , Polimorfismo Genético , Medicina de Precisión , Síndrome de Tourette/tratamiento farmacológico , Síndrome de Tourette/genética , Adulto , Niño , Antagonistas de Dopamina/efectos adversos , Relación Dosis-Respuesta a Droga , Etiquetado de Medicamentos , Monitoreo de Drogas , Pruebas Genéticas , Humanos , Síndrome de QT Prolongado/inducido químicamente , Dosis Máxima Tolerada , Tasa de Depuración Metabólica , Pimozida/efectos adversos , Guías de Práctica Clínica como Asunto , Estados UnidosAsunto(s)
Citocromo P-450 CYP2D6/genética , Antagonistas de Dopamina/administración & dosificación , Antagonistas de Dopamina/farmacocinética , Síndrome de QT Prolongado/prevención & control , Pimozida/administración & dosificación , Pimozida/farmacocinética , Polimorfismo Genético , Medicina de Precisión , Síndrome de Tourette/tratamiento farmacológico , Síndrome de Tourette/genética , HumanosRESUMEN
Despite its superior efficacy, clozapine is helpful in only a subset of patients with schizophrenia unresponsive to other antipsychotics. This lack of complete success has prompted the frequent use of various clozapine combination strategies despite a paucity of evidence from randomized controlled trials supporting their efficacy. Pimozide, a diphenylbutylpiperidine, possesses pharmacological and clinical properties distinct from other typical antipsychotics. An open-label trial of pimozide adjunctive treatment to clozapine provided promising pilot data in support of a larger controlled trial. Therefore, we conducted a double-blind, placebo-controlled, parallel-designed 12-week trial of pimozide adjunctive treatment added to ongoing optimal clozapine treatment in 53 patients with schizophrenia and schizoaffective disorder partially or completely unresponsive to clozapine monotherapy. An average dose of 6.48 mg/day of pimozide was found to be no better than placebo in combination with clozapine at reducing Positive and Negative Syndrome Scale total, positive, negative, and general psychopathology scores. There is no suggestion from this rigorously conducted trial to suggest that pimozide is an effective augmenting agent if an optimal clozapine trial is ineffective. However, given the lack of evidence to guide clinicians and patients when clozapine does not work well, more controlled trials of innovative strategies are warranted.
Asunto(s)
Encéfalo/efectos de los fármacos , Clozapina/agonistas , Pimozida/administración & dosificación , Trastornos Psicóticos/tratamiento farmacológico , Esquizofrenia/tratamiento farmacológico , Adulto , Antipsicóticos/agonistas , Encéfalo/fisiopatología , Método Doble Ciego , Resistencia a Medicamentos/efectos de los fármacos , Resistencia a Medicamentos/fisiología , Sinergismo Farmacológico , Quimioterapia Combinada/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , PlacebosRESUMEN
BACKGROUND: Delusional Parasitosis (DP) is a relatively uncommon condition wherein there is a fixed belief that one is infested with living organisms despite a lack of medical evidence of such infestation. Pimozide has been mooted as specific for the treatment of this condition. Atypical anti-psychotics have received attention in recent years. METHODS: We describe the clinical features and treatment responses in a retrospective review of 20 cases treated at this department over a 5 year period, and selectively review the literature. RESULTS: The majority were treated with atypical anti-psychotics and all subjects who followed up showed varying degrees of clinical improvement irrespective of the anti-psychotic used. CONCLUSION: The evidence for pimozide as first line drug in DP is limited to one small, non-randomized placebo-controlled trial. DP responds well to most anti-psychotics. Prospective randomized trials are needed to clarify optimal treatment of this relatively rare but debilitating condition.
Asunto(s)
Antipsicóticos/administración & dosificación , Infestaciones Ectoparasitarias/psicología , Pimozida/administración & dosificación , Esquizofrenia Paranoide/tratamiento farmacológico , Antipsicóticos/efectos adversos , Benzodiazepinas/administración & dosificación , Benzodiazepinas/efectos adversos , Femenino , Fluoxetina/administración & dosificación , Fluoxetina/efectos adversos , Haloperidol/administración & dosificación , Haloperidol/efectos adversos , Humanos , Imipramina/administración & dosificación , Imipramina/efectos adversos , Masculino , Persona de Mediana Edad , Olanzapina , Pimozida/efectos adversos , Estudios Retrospectivos , Risperidona/administración & dosificación , Risperidona/efectos adversos , Sertralina/administración & dosificación , Sertralina/efectos adversosRESUMEN
A simple, sensitive and specific LC-ESI/MS method was developed for the determination of pimozide in human plasma. Pimozide and cinnarizine (internal standard) were isolated from plasma samples by liquid-liquid extraction. The chromatographic separation was accomplished on a Thermo Hypersil-HyPURITY C18 reversed-phase column (150mmx2.1mm, i.d., 5microm) with the mobile phase consisting of 5mM ammonium acetate (pH 3.5, adjusted with acetic acid)-methanol-acetonitrile (39:5:56, v/v/v). The lower limit of quantification was 0.02ng/mL, and the assay exhibited a linear range of 0.025-12.800ng/mL. The established method has been successfully applied to a bioequivalence study of 2 pimozide formulations in 32 healthy male Chinese volunteers.
Asunto(s)
Antipsicóticos/farmacocinética , Cromatografía Liquida , Espectrometría de Masas , Pimozida/farmacocinética , Administración Oral , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Pueblo Asiatico , Tampones (Química) , Química Farmacéutica , Cromatografía Liquida/normas , Cinarizina/sangre , Estudios Cruzados , Humanos , Masculino , Espectrometría de Masas/normas , Pimozida/administración & dosificación , Pimozida/sangre , Estándares de Referencia , Reproducibilidad de los Resultados , Comprimidos , Equivalencia TerapéuticaRESUMEN
INTRODUCTION: While the dog in vivo model is commonly employed in the later phase of discovery for assessing drug-induced QT prolongation, an early screening assay is valuable when selecting compounds for further development and when compound availability usually is low. One such screening assay is the anaesthetised guinea pig monophasic action potential (MAP) model. The aim of the present study was to evaluate the ability of this model to detect proarrhythmic properties by testing a set of reference compounds with known clinical profile. Moreover, these results were compared to data previously obtained using in vivo canine QT assays (QT PRODACT study). METHODS: Anaesthetised and ventilated male guinea pigs were vagotomised and pretreated with propranolol. After thoracotomy, a pacing electrode was clipped to the left atrial appendage and a suction MAP electrode positioned on the left ventricular epicardium. The drug or corresponding vehicle was injected intravenously in cumulative doses and MAP duration at 90% repolarisation (MAPD90) was recorded during cardiac pacing. RESULTS: The 8 drugs known to be proarrhythmic in the clinic all displayed dose-dependent prolongation of MAPD90, while the 4 drugs devoid of dysrhythmia in man had no effect. When comparing doses producing a 10% MAPD90 increase with doses reported to increase QTc by 10% in dogs a strong correlation was seen (R(2) 0.94 and 0.58 for anaesthetised and conscious dogs, respectively). DISCUSSION: The guinea pig MAP assay identified all clinically positive drugs while negative drugs were without effect on ventricular repolarisation. Furthermore, a good concurrence is shown between the guinea pig and dog models in identifying compounds with proarrhythmic properties. Overall, the study reinforces the anaesthetised guinea pig MAP model as a reliable assay predicting QT liability of new chemical entities and as a highly sensitive early screening model for cardiovascular risk.
Asunto(s)
Potenciales de Acción/efectos de los fármacos , Frecuencia Cardíaca/efectos de los fármacos , Corazón/efectos de los fármacos , Preparaciones Farmacéuticas/administración & dosificación , Potenciales de Acción/fisiología , Amoxicilina/administración & dosificación , Animales , Aspirina/farmacología , Bepridil/administración & dosificación , Captopril/farmacología , Cisaprida/administración & dosificación , Difenhidramina/administración & dosificación , Perros , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos/métodos , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Cobayas , Haloperidol/administración & dosificación , Corazón/fisiología , Corazón/fisiopatología , Inyecciones Intravenosas , Síndrome de QT Prolongado/inducido químicamente , Síndrome de QT Prolongado/diagnóstico , Síndrome de QT Prolongado/fisiopatología , Masculino , Pimozida/administración & dosificación , Piperidinas/administración & dosificación , Propranolol/administración & dosificación , Piridinas/administración & dosificación , Terfenadina/administración & dosificación , Tioridazina/administración & dosificación , Vagotomía , Función Ventricular/efectos de los fármacosAsunto(s)
Antipsicóticos/uso terapéutico , Deluciones/tratamiento farmacológico , Pimozida/uso terapéutico , Antipsicóticos/administración & dosificación , Antipsicóticos/efectos adversos , Benzodiazepinas/administración & dosificación , Benzodiazepinas/efectos adversos , Benzodiazepinas/uso terapéutico , Humanos , Olanzapina , Cooperación del Paciente , Pimozida/administración & dosificación , Pimozida/efectos adversosRESUMEN
Stoats (Mustela erminea), an exotic pest in New Zealand, threaten the conservation of several ground-nesting bird species and broad-scale methods for their control are sought. Females are seasonally monestrous, show a 9-month period of obligatory diapause and usually do not breed more than once in their lives. A bait-delivered agent that terminates diapause and results in a non-viable embryo may have a significant impact on their reproductive success. Prolactin (PRL) is hypothesised to be the only gonadotrophin required for renewal of luteal activity and blastocyst implantation in some mustelids. We investigated the effects of bait-delivered dopamine (DA) antagonists (which stimulate the release of PRL) using a mink model (Mustela vison), a species that maintains a short period of diapause. A bait dose of 0.8 mg kg(-1) of pimozide was more effective in elevating PRL levels than equivalent doses of fluphenazine, sulpiride (P < 0.01) or haloperidol (P < 0.05). Bait doses of 1.6 mg kg(-1) pimozide given at Days 0, 3, 9 and 11 after mating caused a significant reduction in the length of pregnancy compared with a positive control and placebo (46 days v. 51 days), indicating early termination of diapause (P < 0.01). Pimozide doses caused higher elevations in PRL concentration relative to the oral placebo by Day 12, but mean PRL levels fell below all other groups by Day 18. A borderline significant increase in progesterone (P4) secretion compared with the oral placebo was detected at Day 18. These results suggest that bait-delivered pimozide can elevate PRL outside of the normal breeding season and doses of 1.6 mg kg(-1) are effective in terminating embryonic diapause in mink. The implications and limitations of these data are discussed with reference to the use of bait-delivered DA antagonists as a possible means to affect the reproductive success of wild stoats.
Asunto(s)
Anticoncepción/veterinaria , Antagonistas de Dopamina/administración & dosificación , Implantación del Embrión/efectos de los fármacos , Visón , Pimozida/administración & dosificación , Animales , Cruzamiento , Anticoncepción/métodos , Femenino , Alimentos , Control Biológico de Vectores/métodos , Prolactina/metabolismo , Prolactina/fisiología , Estaciones del AñoRESUMEN
Combinations of progesterone, lutenizing hormone releasing hormone analogue (LHRHa), human chorionic gonadotrophin (hCG), and the dopamine-2 (DA2) receptor antagonist 1-[1-[4,4-bis(4-Fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one (Pimozide; Orap) were tested for improvement of spawning rates, oocyte numbers, fertilization and neurulation rates of the Fowler toad (Bufo fowleri). Only treatments combined with progesterone produced large numbers of oocytes. The best treatment on oocyte numbers, neurulation rates, and the number of neurulas was with 5 mg progesterone, 20 mic.g LHRHa, and 0.25 mg Pimozide. Progesterone (5 mg) with 60 mic.g LHRHa gave high spawning rates, oocyte numbers, and fertilization rates but neurulation rates were low. Progesterone alone in high repeated doses did not result in ovulation. High doses of LHRHa (60 mic.g) with hCG, progesterone, and Pimozide gave the greatest number of toads spawning, however, they resulted in low oocyte numbers, fertilization and neurulation rates. A low dose of LHRHa (4 mic.g) with hCG, or hCG alone as a second administration, and progesterone with Pimozide produced few good quality oocytes. Toads were given normal ovulatory doses of hormones 24 or 48 hrs after their initial dose, but these resulted in low oocyte numbers followed by poor fertilization. Overall, these results suggest that progesterone with a dose between 20 mic.g and 60 mic.g of LHRHa may be optimal for the induction of ovulation in these toads. Moreover, Pimozide can supplement low doses of LHRHa but not replace it.
Asunto(s)
Bufonidae/fisiología , Oocitos/efectos de los fármacos , Progesterona/administración & dosificación , Animales , Recuento de Células , Gonadotropina Coriónica/administración & dosificación , Antagonistas de Dopamina/administración & dosificación , Sinergismo Farmacológico , Femenino , Fertilización In Vitro/veterinaria , Hormona Liberadora de Gonadotropina/administración & dosificación , Hormona Liberadora de Gonadotropina/análogos & derivados , Inyecciones Intraperitoneales , Masculino , Pimozida/administración & dosificación , Espermatogénesis/efectos de los fármacosRESUMEN
The purpose of this study was to evaluate a telemetry system for examining QT evaluation in the conscious free-moving guinea pig using 10 reference compounds whose effects on human QT interval are well established: 8 positive references (bepridil, terfenadine, cisapride, haloperidol, pimozide, quinidine, E-4031 and thioridazine), and 2 negative references (propranolol and nifedipine). Pharmacokinetic experiments were also performed for the 8 positive references. Telemetry transmitters were implanted subcutaneously in male Hartley guinea pigs, and the RR and QT intervals were measured. All 8 positive references prolonged QTc (QTc = k x QT/RR(1/2)) 10% or more during the 60 min observation period. When the values of the QTc changes were plotted against the serum concentrations, the resulting curves exhibited an anticlockwise hysteresis loop for all 8 references. In guinea pigs treated with haloperidol, changes of the T-wave shape from positive to flat were observed. The 2 negative references did not prolong the QTc. These findings suggest that the present telemetry guinea pig model is useful for QT evaluation in the early stages of drug development, because of the small body size of guinea pigs and their action potential configuration, which is similar to that of humans.
Asunto(s)
Electrocardiografía/métodos , Síndrome de QT Prolongado/fisiopatología , Telemetría/métodos , Animales , Antiarrítmicos/administración & dosificación , Antiarrítmicos/sangre , Antiarrítmicos/farmacocinética , Antipsicóticos/administración & dosificación , Antipsicóticos/sangre , Antipsicóticos/farmacocinética , Bepridil/administración & dosificación , Bepridil/sangre , Bepridil/farmacocinética , Cisaprida/administración & dosificación , Cisaprida/sangre , Cisaprida/farmacocinética , Modelos Animales de Enfermedad , Cobayas , Haloperidol/administración & dosificación , Haloperidol/sangre , Haloperidol/farmacocinética , Corazón/efectos de los fármacos , Corazón/fisiología , Corazón/fisiopatología , Humanos , Inyecciones Intravenosas , Síndrome de QT Prolongado/inducido químicamente , Síndrome de QT Prolongado/diagnóstico , Masculino , Nifedipino/administración & dosificación , Nifedipino/sangre , Nifedipino/farmacocinética , Pimozida/administración & dosificación , Pimozida/sangre , Pimozida/farmacocinética , Piperidinas/administración & dosificación , Piperidinas/sangre , Piperidinas/farmacocinética , Piridinas/administración & dosificación , Piridinas/sangre , Piridinas/farmacocinética , Quinidina/administración & dosificación , Quinidina/sangre , Quinidina/farmacocinética , Reproducibilidad de los Resultados , Terfenadina/administración & dosificación , Terfenadina/sangre , Terfenadina/farmacocinética , Tioridazina/administración & dosificación , Tioridazina/sangre , Tioridazina/farmacocinéticaRESUMEN
En la última década se puede observar un cambio significativo en las pautas de tratamiento farmacológico para los casos diagnosticados de psicosis Infantiles, en la USMI Virgen del Rocío. Este cambio se ha realizado de forma cautelosa, pasando de un uso importante de las moléculas clásicas (Tiorizacina y Haloperidol) a la utilización paulatina los antippicóticos atípico.Quizá la conclusión más globalizadora sería que se observa una actitud de continua búsqueda de nuevas posibilidades de tratamiento lo que conlleva la necesidad de mantenerse atentos y conocer los avances en psicofarmacología que nos permitan ofrecer la mejor posibilidad terapeútica para los niños y adolescentes afectos de trastornos tan graves como son la esquizofrenia cuadros psicóticos (AU)
Asunto(s)
Adolescente , Femenino , Preescolar , Masculino , Niño , Humanos , Servicios de Salud Mental/estadística & datos numéricos , Prescripciones de Medicamentos/estadística & datos numéricos , Antipsicóticos/administración & dosificación , Antipsicóticos/farmacología , Trastornos Psicóticos/tratamiento farmacológico , Tioridazina/administración & dosificación , Tioridazina/farmacología , Haloperidol/administración & dosificación , Haloperidol/farmacología , Pimozida/administración & dosificación , Pimozida/farmacología , Risperidona/administración & dosificación , Risperidona/farmacologíaRESUMEN
The aim of this study was to identify the major C21 steroids produced in vivo during artificially induced final oocyte maturation and spawning in female common dentex (Dentex dentex). During the spawning season, mature females were treated with a gonadotropin-releasing hormone agonist (GnRHa)-loaded delivery system, with or without pimozide (given as a single dose at the beginning of the experiment). Blood samples were collected at various intervals during the experiment and were assayed for GnRHa, 17,20beta-dihydroxy-4-pregnen-3-one (17,20beta-P), and 17,20beta,21-trihydroxy-4-pregnen-3-one (17,20beta,21-P). A higher percentage of ovulated females was observed in GnRHa-implanted fish, which produced over 10 times more eggs than controls. Relative fecundity was highest in the GnRHa + pimozide group and lowest in controls. The viability of naturally released eggs was low (2 to 15%) in all groups. Plasma concentrations of 17,20beta-P in GnRHa-implanted fish did not increase, but those in control fish decreased, such that there was a significant difference between control and treated fish between 2 and 10 days after treatment. In another experiment, ovulating common dentex were injected intramuscularly with a single dose of 50 microg kg(-1) of GnRHa in saline and were sampled for blood at 0, 3, 6, 12, and 24 h postinjection. A single water sample was taken from the tanks at 9 h postinjection, the tanks having been emptied and refilled at 6 h. Measurements were made of plasma and water concentrations of free and conjugated 17,20beta-P, 17,20beta,21-P, 17beta-oestradiol (E2), and GnRHa (plasma only). The GnRHa injection increased plasma levels of all steroids, with free 17,20beta-P reaching maximal levels within 3 h. GnRHa treatment also increased the amounts of free and conjugated steroids released into the water between 6 and 9 h.